Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne

Journal of the American Academy of Dermatology

Volumn 51, Issue 5, 2004, Pages 709-717

  Digiovanna, John J ^a   Langman, Craig B ^a   Tschen, Eduardo H ^a   Jones, Terry ^a   Menter, Alan ^a   Lowe, Nicholas J ^a   Eichenfield, Lawrence ^a   Hebert, Adelaide A ^a   Pariser, David ^a   Savin, Ronald P ^a   Smith, Stacy R ^a   Jarratt, Michael ^a   Rodriguez, David ^a   Chalker, Dan K ^a   Kempers, Steven ^a   Ling, Mark ^a   Rafal, Elyse S ^a   Sullivan, Sabra ^a   Kang, Sewon ^a   Shah, Leena P ^a   Wu, Emily ^a   Newhouse, Julie ^a   Pak, Jonathan ^a   Eberhardt, Douglas R ^a   Bryce, Graeme F ^a   McLane, John A ^a   Ondovik, Michael ^a   Chin, Catherine ^a   Khoo, Ko Chin ^a   Rich, Phoebe ^a   more..

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ACNE; ADOLESCENT; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CHEILITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRY SKIN; FEMALE; HIP; HUMAN; HYPEROSTOSIS; LIMB INJURY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SPRAIN; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; BONE DENSITY; CHILD; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIP; HUMANS; HYPEROSTOSIS; ISOTRETINOIN; LUMBAR VERTEBRAE; MALE; PROSPECTIVE STUDIES;

EID: 8744232244     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.04.032     Document Type: Article

References (32)

1. Farrell L.N., Strauss J.S., Stranieri A.M. The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol. 3:1980;602-611
2. Peck G.L., Olsen T.G., Yoder F.W., Strauss J.S., Downing D.T., Pandya M., et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med. 300:1979;329-333
3. Jones H., Blanc D., Cunliffe W.J. 13-cis-retinoic acid and acne. Lancet. 2:1980;1048-1049
4. Silverman A.K., Ellis C.N., Voorhees J.J. Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol. 16:1987;1027-1039
5. DiGiovanna J.J. Isotretinoin effects on bone. J Am Acad Dermatol. 45:(Suppl):2001;S176-S182
6. Pittsley R.A., Yoder F.W. Skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med. 308:1983;1012-1014
7. Ellis C.N., Madison K.C., Pennes D.R., Martel W., Voorhees J.J. Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol. 10:1984;1024-1029
8. Pennes D.R., Ellis C.N., Madison K.C., Voorhees J.J., Martel W. Early skeletal hyperostoses secondary to 13-cis-retinoic acid. Am J Radiol. 142:1984;979-983
9. Kilcoyne R.F., Cope R., Cunningham W., Nardella F.A., Denman D., Franz T.J., et al. Minimal spinal hyperostosis with low-dose isotretinoin therapy. Invest Radiol. 21:1986;41-44
10. Kocijancic M. 13-cis-Retinoic acid and bone density. Int J Dermatol. 34:1995;733-734
11. Margolis D.J., Attie M., Leyden J.J. Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol. 132:1996;769-774
12. Leachman S.A., Insogna K.L., Katz L., Ellison A., Milstone L.M. Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol. 135:1999;961-965
13. DiGiovanna J.J., Sollitto R.B., Abangan D.L., Steinberg S.M., Reynolds J.C. Osteoporosis is a toxic effect of long-tern etretinate therapy. Arch Dermatol. 131:1995;1263-1267
14. Allen B.S., Smith G. Various parameters for grading acne vulgaris. Arch Dermatol. 118:1982;23-25
15. Heaney R.P., Abrams S., Dawson-Hughes B., Looker A., Marcus R., Matkovic V., et al. Peak bone mass. Osteoporos Int. 11:2000;985-1009
16. Bachrach L.K., Hastie T., Wang M.-C., Narasimhan B., Marcus R. Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab. 84:1999;4702-4712
17. Lenchik L., Leib E.S., Hamdy R.C., Binkley N.C., Miller P.D., Watts N.B. Executive summary, International Society for Clinical Densitometry position development conference, Denver, Colorado, July 20-22, 2001. J Clin Densitom. 5:(Suppl):2002;S1-S3
18. Hamdy R.C., Petak S.M., Lenchik L. Which central dual x-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis? J Clin Densitom. 5:(Suppl):2002;S11-S18
19. Lenchik L., Kiebzak G.M., Blunt B.A. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 5:(Suppl):2002;S29-S38
20. Pennes D.R., Martel W., Ellis C.N., Voorhees J.J. Evolution of skeletal hyperostoses caused by 13-cis-retinoic acid therapy. Am J Radiol. 151:1988;967-973
21. Carey B.M., Parkin G.J.S., Cunliffe W.J., Pritlove J. Skeletal toxicity with isotretinoin therapy: a clinico-radiological evaluation. Br J Dermatol. 119:1988;609-614
22. Török L., Budai S., Kása M., Kádár L. Bone x-ray examinations in patients treated with isotretinoin: a prospective study. Br J Dermatol. 118:1988;134-135
23. Milstone A.M., Milstone L.M. Is retinoid induced osteopenia reversible? Arch Dermatol. 138:2002;1516-1517
24. Takada M., Grampp S., Ouyang X., Engelke K., Genant H.K. A new trabecular region of interest for femoral dual x-ray absorptiometry: short-term precision, age-related bone loss, and fracture discrimination compared with current femoral regions of interest. J Bone Miner Res. 12:1997;832-838
25. Fournier P.E., Rizzoli R., Slosman D.O., Theintz G., Bonjour J.P. Asynchrony between the rates of standing height gain and bone mass accumulation during puberty. Osteoporos Int. 7:1997;525-532
26. Katzman D.K., Bachrach L.K., Carter D.R., Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab. 73:1991;1332-1339
27. Bachrach L.K. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab. 12:2001;22-28
28. Matkovic V., Jelic T., Wardlaw G.M., Ilich J.Z., Goel P.K., Wright J.K., et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. J Clin Invest. 93:1994;799-808
29. Strauss J.S., Leyden J.J., Lucky A.W., Lookingbill D.P., Drake L.A., Hanifin J.M., et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol. 45:2001;187-195
30. Strauss J.S., Leyden J.J., Lucky A.W., Lookingbill D.P., Drake L.A., Hanifin J.M., et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol. 45:2001;196-207
31. Strauss J.S., Rapini R.P., Shalita A.R., Konecky E., Pochi P.E., Comite H., et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 10:1984;490-496
32. Michaëlsson K., Lithell H., Vessby B., Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 348:2003;287-294